Lots of institutions wanting to meet with Novavax STIFL, PIPER, and JP MORGAN?? Hedge Funds are reporting holdings of Novavax. SHORTS ARE GOING TO GET SMASHED.
Something big is up and it's NOT JUST THE STOCK PRICE!
HUGE DEAL!!!! Hate to be short goign into this conference. HAHAHA
You will see that position go down when it's updated at the end of the month. If they aren't covering, they will be. This stock is going higher.
Big News Coming Friday morning???
Sentiment: Strong Buy
What a presentation regarding the new Phase 3 RSV-F vaccine for Novavax. Everyone seemed very excited. This is a huge deal for Novavax and the World!!!
Sentiment: Strong Buy
This stock is going up so fast, you won't have time to cover. Time to cover is now! Big institutions LOVED the RSV-F presentations at the Stifel 2015 Healthcare Conference. They will be buying shares of Novavax for their Healthcare Funds this week thru the end of the year. Good Luck Shorts!
When Bill Gates first became interested in vaccines, he became obsessed with one fact: that it took a decade or more after a vaccine became available in rich countries before it reached children in poor ones.
Now Gates’ foundation is introducing a new tool for closing that gap. The Bill and Melinda Gates Foundation will spend up to $89 million to fund the development of a vaccine against viral pneumonia. In return, the vaccine’s maker, Novavax, will make the shot available at an undisclosed, but cheap, price in developing countries if it proves effective.
The arrangement is a “big step forward,” says Keith Klugman, the director for pneumonia at the Gates Foundation. “We felt that this was a worthwhile investment to make sure that if the vaccine does work, and if it is licensed, that it will be made available to infants in the developing world virtually simultaneously with the developed world.”
Novavax’s vaccine targets the respiratory syncytial virus (RSV). This is the top cause of pneumonia in children under 1. Each year, RSV kills 160,000 children across the world, and is a leading cause of hospitalization in U.S. hospitals. It also causes respiratory infections in people of all ages, leading to problems in the elderly. But so far, the virus has evaded all attempts to create a vaccine to stop it.
Don't you find it kind of interesting that the foundation gives Novavax almost $90 million ahead of the Phase 3 annoucement. You think they just "toss" money around like that for nothing? This is HUGE!!!!!!!
Has anyone been listening to Novavax at Stifel 2015 Healthcare Conference? All those people clapping about the results and Phase 3 RSV-F accomplishment? HUGE!!!! SHORTS are going to get CRUSHED!!!!